FDA Approved Medical Products for:

Myelodysplastic syndromes

The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products.

Generic Name Decitabine
Trade Name
(Manufacturer Name)
Dacogen® (injection)
(Eisai Medical Research, Inc.)
Indication
The FDA has approved this product to be used in this manner.
For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
More Information about this product Drug Information Portal

Generic Name Lenalidomide
Trade Name
(Manufacturer Name)
Revlimid®
(Celgene Corporation)
Indication
The FDA has approved this product to be used in this manner.
For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy.
More Information about this product Drug Information Portal

Generic Name Azacitidine
Trade Name
(Manufacturer Name)
Vidaza®
(Celgene Corporation)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blas
More Information about this product Drug Information Portal
Medline Plus Health Information